Grace Therapeutics, Inc. (GRCE)
Data as of , from SEC Form 4 filings.
Net insider buying (90d)Watch GRCE
See up to 3 months of GRCE. The 7-day demo opens the 1M and 3M ranges and puts GRCE on your watchlist.
Start 7-day demoLatest GRCE insider trades
About Grace Therapeutics, Inc. (GRCE)
The SEC lists Grace Therapeutics, Inc. under CIK 0001444192, in pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
GRCE Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 14 | 232,137 | $487K |
| Grant or award | 8 | 427,870 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
GRCE insider transactions (Form 4)
2720 Form 4 filings on record, the earliest from May 9, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 2,077 | $2.02 | $4K | |
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 5,340 | $2.04 footnote F2 | $11K | |
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 7,215 | $2.02 | $15K | |
| ||||||
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 38,796 | $2.04 footnote F2 | $79K | |
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 20,000 | $2.07 footnote F3 | $41K | |
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 1,694 | $2.06 | $3K | |
| ||||||
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 9,771 | $2.10 | $21K | |
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 5,318 | $2.10 | $11K | |
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 9,771 | $2.10 | $21K | |
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 5,318 | $2.10 | $11K | |
| Edward Neugeboren - Director | Grant or award | Stock Option (Right to Buy) | 12,200 | $0.00 | - | |
| A. Brian Davis - Director | Grant or award | Stock Option (Right to Buy) | 0 | $0.00 | - | |
 Vimal Kavuru - Director | Grant or award | Stock Option (Right to Buy) | 12,200 | $0.00 | - | |
 George Kottayil - Director | Grant or award | Stock Option (Right to Buy) | 12,200 | $0.00 | - | |
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 9,393 | $2.10 footnote F2 | $20K | |
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 5,836 | $2.09 footnote F3 | $12K | |
| ||||||
| Prashant Kohli - Officer | Open-market purchase | Common Stock | 100,000 | $2.14 | $214K | |
| Amresh Kumar - Officer | Grant or award | Stock Option (Right to Buy) | 35,760 | $0.00 | - | |
| R. Loch Macdonald - Officer | Grant or award | Stock Option (Right to Buy) | 54,690 | $0.00 | - | |
| Prashant Kohli - Officer | Grant or award | Stock Option (Right to Buy) | 267,160 | $0.00 | - | |
| Robert J. Delaversano - Officer | Grant or award | Stock Option (Right to Buy) | 33,660 | $0.00 | - | |
| Opaleye Management Inc. - 10% Owner | Open-market purchase | Common Stock, par value $0.0001 per share | 11,608 | $2.09 footnote F2 | $24K | |
| ||||||
| Vimal Kavuru | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| George Kottayil | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| Edward Neugeboren | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| A. Brian Davis | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
| A. Brian Davis | Grant or award | Stock Option (Right to Buy) | 10,000 | $0.00 | - | |
Item 5.07
Item 2.02, 9.01
Item 1.01, 3.02, 8.01, 9.01
Item 8.01, 9.01
GRCE insider trading FAQ
What is the latest insider trade for GRCE?
Grace Therapeutics, Inc. (GRCE) had 15 insider filings in the last 90 days, with the most recent on 2026-10-13. The full record for GRCE runs to 20 Form 4 filings, the earliest from 2025-05-09. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying GRCE stock?
14 insider purchases of GRCE were filed in the last 90 days, totaling $487K.
How many insiders are selling GRCE stock?
No insider sales of GRCE were filed in the last 90 days.
Where can I see GRCE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects GRCE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Opaleye Management Inc. view on EDGAR
- - Opaleye Management Inc. view on EDGAR
- - Opaleye Management Inc. view on EDGAR
- - Opaleye Management Inc. view on EDGAR
- - Edward Neugeboren view on EDGAR
- - A. Brian Davis view on EDGAR
- - Vimal Kavuru view on EDGAR
- - George Kottayil view on EDGAR
- - Opaleye Management Inc. view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where GRCE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow GRCE with a 7-day demo
- GRCE on your watchlist
- Every GRCE Form 4 filing on record
- Up to 3 months of GRCE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
